Sanofi, confident in the growth of its influenza vaccines, has committed to spending $202 million to build a new manufacturing facility at its Val-de-Reuil site in north-western France.
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to expand its supply of influenza vaccine, VaxigripTetra, to up to 70 countries in six continents. Sanofi Pasteur remains the sole influenza vaccine producer in the country.
The new facility, which will be the only site of its kind in France, will be completed by 2021 and should begin producing vaccines by 2022.
Read the press release